⚕ GalenOps field
←

SITE004-0144

withdrawn

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2022-08-16

AEs
6
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-10-21 (study day 56); relationship: N

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-04 (study day 70); relationship: N

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-09 (study day 75); relationship: not assessed

severe assessed

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-18 (study day 114); relationship: Y

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-08 (study day 225); relationship: not assessed

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-04-15 (study day 232); relationship: Y

Data queries

No data queries.